Regarding “Does simvastatin save lives; If so, when and in whom?”  by Vos, Eddie et al.
plantable pressure sensors. Our study is the first report on late
pressure measurements in the endoleak nidus (flow channel) and
the thrombus with the same technique and confirms a difference in
pressure gradient between these two locations. The previously
reported association of aneurysm shrinkage with intra-sac depres-
surization in the absence of endoleaks2 seems also to be present
with endoleaks. The degree of depressurization seems nevertheless
to be different. Pressure measurements in the presence of an
endoleak need, therefore, to be assessed cautiously, no matter how
the measurement was obtained.
Implantable pressure sensors have the advantage of allowing
repeated measurements over time.3,4 We share the view that pressure
sensorsmay eventually becomeuseful in the follow-upof patients after
EVAR. Before that happens, the aforementioned issues common to
all pressuremeasurement systems in the presence of endoleaks need to
be solved and the long-term accuracy of implantable sensors needs to
be established. Implantable devices have been validated in the imme-
diate period after EVAR, but thrombus can change with time acquir-
ing a non-uniform structure5-7 that can influence transmission of
pressure.8,9 Some of these issues are expected to be answered by
on-going trials, which will hopefully include a validation against the
validated direct intra-aneurysm sac pressure measurements (DISP)
with tip-pressure sensors.
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Regarding “Does simvastatin save lives; If so, when
and in whom?”
In theHeart Protection Study,1 it was suggested that cholesterol-
lowering therapy with simvastatin can reduce the risk of major
vascular events among people with peripheral artery disease
(PAD). However, a clearly defined effect on total mortality was not
reported. In 1992, four of the initiators of the Heart Protection
Study (HPS) called for larger total mortality trials to generate data
in six named patient subgroups.2 In 2001, after their study was
completed, the press release started with the words “LIFE-SAVER”
but it gave no data on deaths.3 Similarly, the current HPS report
avoided the subject by curiously combining deaths with aneurysm
repairs, only to find a small increase on simvastatin for this com-
bined endpoint.
Furthermore, HPS found no significant mortality benefit in
women, and it now seems that this could also be true for patients
with baseline PAD.1 The authors admitted that much of their
combined endpoint event benefit in PAD patients was in revascu-
larizations, and after they retrospectively redefined “peripheral
vascular events” to include all noncardiac revascularizations includ-
ing carotid procedures.
Revascularizations are procedures that may or may not affect
mortality or future cardiovascular events,4 and it is, thus, important
to report deaths and true disease endpoints separately. Regardless,
despite the absence of noncombined endpoint numbers and num-
bers needed to treat, the article and its debating author, Dr
Bulbulia, stated repeatedly that patients with PAD “should be” on
statin (presumably for life) and that there “should be no threshold for
initiation of statin therapy”.1 We believe that this is not supported
by the grouped endpoint data presented, especially since total
deaths are not clearly reported for all participant groups.
Interestingly, HPS, 4S5 and LIPID6 are the only three large
statin trials to show a brief period of mortality benefit, almost
certainly in some men only. Such benefit appeared after about 1.5
years of use and ended about 2 or 3 years later. Such time-
dependent and time-limited mortality effect can be shown by
releasing the relevant disease and group specific time curves indi-
vidually.
The authors of HPS should therefore finally release a table for
total deaths, heart attacks, amputations, and other disease end-
points and related numbers needed to treat, with confidence levels,
in women, men, and diabetics, and in this case for PAD patients for
1, 3, and 5 years of simvastatin treatment regarding these end-
points. Without such curves and year-by-year disease and group
specific numbers needed to treat, prescribers lack crucial data
relevant to their patients. Patients deserve to be told their odds of
avoiding death and each of the various lesser disease endpoints and
for how long they need to take statin to attain these results, and
when the effect may no longer exist or be incremental.
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Reply
Previously published results from the Heart Protection Study
(HPS) show clearly that lowering LDL cholesterol by about 1
mmol/L (38 g/dL) with simvastatin produced a highly significant
13% (SE 4) relative reduction in all-cause mortality (1328 [12.9%]
simvastatin-allocated vs 1507 [14.7%] placebo-allocated deaths; P
.0003) during the scheduled 5-year treatment period.1 This very
definite survival benefit reflected the combined impact of a highly
significant 17% (SE 4) relative reduction in vascular deaths (781
[7.6%] vs 937 [9.1%]; P .00001) and of a nonsignificant difference
in nonvascular mortality (547 [5.3%] vs 570 [5.6%]; P  .4). A
subsequent report showed that there were similar relative reductions
in vascular deaths (and nonfatal major vascular events), with no
evidence of any adverse effects on nonvascular deaths (or cancers), in
a range of different circumstances (including among women).2 The
reduction in vascular mortality started to emerge during the first year
of statin treatment and increased during each subsequent year of
treatment, with no adverse effect on nonvascular mortality emerging
during or after the scheduled treatment period.1-3
Meta-analyses of individual patient data from large random-
ized trials (including HPS) have reliably demonstrated that
statin therapy reduces vascular mortality substantially, while
producing little or no effect on nonvascular mortality.4 Conse-
quently, the relative reduction in all-cause mortality in some
particular circumstance is determined not only by the size of the
relative reduction in vascular mortality with statin therapy but
also by the ratio of vascular to nonvascular deaths. Moreover,
separate assessment of the effects of statin therapy on vascular
mortality and on nonvascular mortality in such circumstances
(considered in the context of the overall findings for cause-
specific mortality and for the much larger numbers of nonfatal
vascular and nonvascular events) is likely to provide a more
sensitive assessment of any benefits and hazards than would
direct comparisons of deaths from all-causes.
With regard to the subgroup of patients in HPS with
peripheral arterial disease (PAD), the observed 10% (95% CI
-5-12) relative reduction in vascular mortality (10.2% simvasta-
tin vs 11.2% placebo) was not significantly different from the
23% (12-32) relative reduction observed among the other high-
risk patients studied (heterogeneity P value  .1). Moreover,
this lack of heterogeneity of benefit with statin therapy was
reinforced by the similar (heterogeneity P value  .5), and
highly significant, relative reductions in major vascular events
(MVE): (ie, vascular deaths, heart attacks, strokes, and revascular-
izations) among patients with PAD (22% [SE 4]; P  .0001) and
the other high-risk patients (25% [SE 3]; P  .0001).5 The
apparent lack of effect on the small number of aneurysm deaths or
repairs should be considered in the context of these large reduc-
tions in vascular events. In terms of the absolute benefits in HPS,
allocation to statin therapy prevented 63 (11) first MVEs, and 116
(21) first and subsequent MVEs, per 1000 PAD patients. This
corresponds to a “number needed to treat” to prevent a first MVE
of 16 (SE 3), although this underestimates the benefit of actually
taking a statin because only about two-thirds of patients complied
with their allocated treatment during the 5-year study period. In
terms of safety, as was observed overall in HPS, there was no
apparent effect on nonvascular mortality among the patients with
PAD (7.3% simvastatin vs 7.7% placebo; hazard ratio 0.94; 95% CI
0.79-1.12; P  NS).
In conclusion,HPS has shown that 40mg simvastatin daily safely
reduces both vascular mortality and major vascular morbidity in
patients with PAD and in other high-risk patients, without adverse
effects on nonvascularmortality ormajor nonvascularmorbidity. It is,
therefore, entirely reasonable to conclude that vascular surgeons
should consider statin therapy for all patients with proven PAD
irrespective of age, gender, and baseline lipid levels.
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Regarding “Light assisted stab phlebectomy: Report
of a technique for removal of lower extremity
varicose veins”
In the article by Lawrence and Vardanian,1 the authors reported
on light assisted stab phlebectomy. I was amazed by how a simple
procedure can be made so eloquently complicated. We have per-
formed stab avulsion phlebectomies on more than 2000 patients in
our office without sedation. We use 1% local lidocaine anesthetic
injected only into the site of the 2 mm puncture over the previously
marked vein. Tumescent anesthesia is not required or used since we
find that it oozes from the incision making application of Steri-strip
closure unreliable. Provided that the vein itself is removed, without
any adjacent subcutaneous tissue, patients feel no pain. At most, they
notice a pulling sensation. Simple finger pressure for a minute or two
prevents bleeding even from a large varicosity.
No sutures are required to close the incision but simply
Steri-strips. We do not wrap the leg but rather use a 30 to 40 mm
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